FLT3 and acute myeloid leukemia: Two large randomized clinical trials of induction and consolidation chemotherapy plus gilteritinib vs midostaurin in FLT3 mutated AML patients are ongoing in the US (PrECOG trial) (NCT03836209)) and in Europe (HOVON 156 AML / AMLSG 28–18 trial (NCT04027309)).